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Abstract
Bovine Respiratory Disease is the most costly disease that affects beef and dairy
cattle industry. Its etiology is multifactorial, arising from predisposing environ-
mental stress conditions as well as the action of several different respiratory
pathogens. This situation has hindered the development of effective control
strategies. Although different type of vaccines are available, many currently
marketed vaccines are based on inactivated cultures of the main viral and bacterial
agents involved in this pathology. The molecular composition of commercial
veterinary vaccines is a critical issue. The present work aims to define at the
proteomic level the most relevant valence of a line of commercial respiratory
vaccines widely used in Central and South America. Since Mannheimia
haemolytica is responsible for most of the disease associated morbid-mortality,
we focused on the main proteins secreted by this pathogen, in particular
Leukotoxin A, its main virulence factor. By Western blot analysis and mass
spectrometry, Leukotoxin A was identified as a major component of
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M. haemolytica culture supernatants. We also identified other ten M. haemolytica
proteins, including outer membrane proteins, periplasmic transmembrane solute
transporters and iron binding proteins, which are relevant to achieve protective
immunity against the pathogen. This work allowed a detailed molecular
characterization of this vaccine component, providing evidence of its quality and
efficacy. Furthermore, our results contributed to the identification of several
proteins of interest as subunit vaccine candidates.
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1. Introduction
Bovine Respiratory Disease (BRD) is one of the leading causes of death and
economic loss for the beef and dairy cattle industry. It has an estimated annual cost
to the worldwide cattle industry of over $3 billion (Potter, 2015). This
multifactorial syndrome can be caused either by viral or bacterial pathogens.
Viral agents include bovine respiratory syncytial virus (BRSV) (Gershwin et al.,
2000), parainfluenza III virus (PI-3) (Fulton et al., 2000), bovine viral diarrhea
virus (BVDV) (Ridpath, 2010) and bovine corona virus (BCV) (Autio et al., 2007).
These respiratory viruses along with some mycoplasmal agents are generally the
primary infectious agents involved in BRD (Potter, 2015). This initial infection
establishes a respiratory environment predisposing to the colonization and
replication of pathogenic bacteria, including Mannheimia haemolytica (Al-Ghamdi
et al., 2000), Pasteurella multocida (Dabo et al., 2007) and Histophilus somni
(Corbeil, 2007), the former being responsible for up to 50% of the disease
associated mortality (Narayanan et al., 2002; Potter, 2015). M. haemolytica is a
Gram negative opportunistic bacterium. Although it is a common bacterium of the
upper respiratory tract and nasopharynx of healthy ruminants, it can also act as an
opportunistic pathogen infecting the lower respiratory tract under stressful
situations such as shipping, adverse environmental conditions or previous
respiratory viral infection (Youssef et al., 2004; Orouji et al., 2012).
Being BRD a multifactorial disease, the development of effective control strategies
has been difficult to accomplish. Vaccination against viral and bacterial pathogens
involved in BRD is a useful tool to reduce the risk of this disease. Many
commercial respiratory vaccines are composed by inactivated cultures of the most
relevant pathogens (Edwards, 2010; Rodrigues et al., 2015). These multivalent
formulations are designed to reduce the impact of viral infections and to neutralize
the severe associated bacterial infections. Therefore, to guarantee the efficacy of
BRD vaccines, it is important to achieve a complete characterization of the
antigens included in the vaccine and to verify the presence of those molecules
critical for establishing an efficient immunological protection.
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In this work we attempt to characterize the main proteins of M. haemolytica in a
polyvalent inactivated BRD line of vaccines currently commercialized in Central
and South America (Neumosan, Virbac Uruguay S.A. (former Santa Elena), http://
www.santaelena.com.uy). Among them we emphasize the study of Leukotoxin A
(LKT), its main virulence factor, which has been shown to play an important role
in the development of a protective immunity against the pathogen (Confer et al.,
2009).
LKT is a potent cytolytic toxin, with an apparent molecular weight (MW) of 105
kDa, actively secreted by all serotypes of the bacterium during the logarithmic
phase of in vitro growth (Shewen and Wilkie, 1985; Chang et al., 1987). It belongs
to the family of the RTX (repeat in toxin) pore-forming cytolysins, which have
been linked with the virulence of other bacterial species (Lo et al., 1987; Lainson
et al., 1996). It specifically targets ruminant leukocytes and plays a major role in
pathogenesis of BRD by impairing the primary lung defense mechanism and by
inducing inflammation as a consequence of leukocyte lysis (Conlon et al., 1991).
This phenomenon has been correlated with its ability to bind and interact with the
ruminant beta2-integrin Lymphocyte Function-associated Antigen 1 (LFA-1)
(CD11a/CD18) (Zecchinon et al., 2005; Singh et al., 2011). Neutralizing
antibodies generation against the cytolytic toxin is relevant for achieving a high
level of protection (Mosier et al., 1989). Immunity against M. haemolytica also
requires antibodies against bacterial cell surface antigens (Shewen and Wilkie,
1988) and iron-regulated outer membrane proteins (Potter et al., 1999).
Our aim is to bring more insight into the molecular composition of a M.
haemolytica inactivated antigen used in bovine commercial vaccines, focusing on
the identification of relevant secreted or surface-exposed proteins. This knowledge
will support the development of specific quality control techniques to assist the
optimization and standardization of the industrial vaccine production process.
2. Materials and methods
2.1. Laboratory scale M. haemolytica culture
A seed culture was prepared by inoculation of an aliquot of master seed bank
(MSB) of M. haemolytica serotype A1 (production strain code B059) in TSB-BHI
(Tryptic Soy Broth, Brain Heart Infusion, Porcine) and incubation at 37.0 ± 1.0 °C,
for 12 h with orbital agitation (220 rpm). Inoculum was prepared by a 1:100
dilution of the seed culture in TSB-BHI and further incubation at 37.0 ± 1.0 °C
with orbital agitation until an optical density at 600 nm (OD600nm) of 0.2 to 0.3
units was reached. A benchtop fermentor (Biostat A, New Brunswick) with 2 L of
fermentation media (TSB-BHI supplemented with 0.4% glucose) was inoculated
with 20 mL of the inoculum culture (1:100 dilution). The fermentation culture was
grown at 37.0 ± 1.0 °C with dissolved oxygen set above 40% and variable
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agitation. During fermentation, samples were taken every one hour to measure
OD600nm, dissolved oxygen (%), glucose concentration (mg/dL) and pH. The
culture was harvested when it reached stationary growth phase. Samples and the
final culture were centrifuged at 8000×g for 30 min at 4 °C and culture
supernatants were stored at −20 °C.
2.2. Industrial M. haemolytica antigen preparation
M. haemolytica culture for vaccine antigen preparation was performed following
the industrial standardized protocol. Culture media used was developed by Virbac
Uruguay S.A. and is based on protein hydrolysates, yeast extract, dextrose, and
sodium and potassium salts. The inoculum was prepared as previously described
using 1 vial of production seed of M. haemolytica serotype A1 (production strain
code B059). The production fermentor was inoculated with a 1:100 dilution of the
inoculum and the culture was performed at 37 °C with automatic agitation and
aeration until the end of the logarithmic growth phase. After harvesting, culture
was inactivated by incubation at 37 °C with formaldehyde 0.5% (v/v) during 24 h.
To obtain culture supernatant the inactivated culture was centrifuged at 8000×g for
30 min at 4 °C. Inactivated culture supernatant was stored at −20 °C.
2.3. Recombinant LKT production
Specific primers were designed to amplify a portion of LKT which contains the C-
terminal domain of the protein. An in silico prediction of the location of linear B-
cell epitopes was performed using Bepipred algorithm (Larsen et al., 2006). As
previously reported (Lee et al., 2001), the portion of LktA with more immunogenic
epitopes was the C-terminal domain. Therefore, a sequence including the main
predicted epítopes (amino acid 713 to 873) was selected. M. haemolytica
(production strain code B059) was cultured as the seed culture described above.
Culture was centrifuged at 10000×g and the cell pellet was stored at −70 °C. M.
haemolytica genomic DNA was extracted using a standard protocol (Ausubel et al.,
1999) and partial LKT sequence was amplified by PCR. For LKT expression,
restriction sites were included in primers for a directional cloning of LKT sequence
in pET28a(+) vector (Novagen). E. coli BL21 DE3 (Novagen) competent cells
were transformed with the construct and stored at −70 °C in 15% glycerol. Plasmid
DNA was isolated from E. coli using a commercial kit (QiaPrep Spin Miniprep,
Qiagen). Plasmid sequence was confirmed by DNA sequencing at Institut Pasteur
Montevideo (Uruguay). For LKT expression, a culture was performed in ZYM-
5052 auto induction medium (Studier, 2005) for 18–20 h at 37.0 ± 1.0 °C. As
expected, by SDS-PAGE a band of approximately 40 kDa corresponding to the
recombinant protein was observed. The protein was purified by IMAC chromatogra-
phy (HisTrap HP, GE Healthcare) in an ÄKTA Purifier 100 (GE Healthcare). The
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purified protein was dialyzed against PBS 1X pH 7.4 and quantified by BCA (Pierce
BCA Protein Assay Kit, Thermo Scientific).
2.4. Rabbit anti-LKT serum production and evaluation
Two New Zealand white rabbits (2.5 Kg body weight) were maintained in the
experimental animal facility (Instituto de Higiene, Universidad de la República,
Uruguay) in accordance with animal procedures approved by the Honorary
Commission of Animal Experimentation (CHEA protocol No 071140-000771-11).
Both rabbits were immunized subcutaneously with 50 ug of recombinant LKT, on
days 0 and 21 of the immunization protocol. Blood samples were taken on days 21,
45 and 115, and sera were prepared and stored at −20 °C. Serum titers were
determined by ELISA using 0.1 μg/well of recombinant LKT for coating, serum
dilutions of 1:100 to 1:100.000, and conjugate dilution of 1:10.000 (Goat anti-
rabbit IgG (whole molecule)—Peroxidase, Sigma). High titer sera were pooled and
purified by protein A chromatography (HiTraprProtein A, GE Healthcare). Purified
IgG reactivity against native and recombinant LKT was evaluated by Western blot
as described below.
2.5. SDS-PAGE and Western blot analysis
Culture supernatants were analyzed by 12% SDS-PAGE and coomassie blue
staining (Ausubel et al., 1999). Molecular weight markers used were PageRuler
Prestained Protein Ladder (Thermo Scientific) and Prestained Protein Ladder
Broad Range (NEB).
For Western blot analysis, proteins were transferred onto a nitrocellulose
membrane (Hybond-C Extra, Amersham Biosciences) for one hour at 400 mA.
Rabbit antibodies against recombinant LKT, produced and purified by our work
group, were used to identify LKT in culture supernatants. Briefly, membranes were
incubated for 1 h at room temperature with anti-LKT antibodies at final
concentration of 17.5 μg/mL in PBS 1X pH 7.4, 5% low fat milk, with gentle
agitation. For antigen-antibody detection membranes were incubated for 1 h at
room temperature with a 1:5000 dilution of anti-rabbit IgG (whole molecule)—
alkaline phosphatase antibody produced in goat (Sigma) in PBS 1X pH 7.4, 5% low
fat milk. The intensity of resulting bands was quantified using a Molecular Imaging
Software (Carestream Health Inc).
For immune response evaluation bovine sera obtained from a calf infected with M.
haemolytica and from a healthy calf were gently provided by Virbac Uruguay.
Inactivated and non inactivated culture supernatant samples analyzed by SDS-
PAGE were transferred onto membranes, as previously described. Membranes
were incubated for 1 h at room temperature with a 1:500 dilution of each serum and
afterwards for 1 h at room temperature with a 1:5000 dilution of anti-bovine
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IgG–HRP (Novex), all in PBS 1X pH 7.4, 5% low fat milk. Detection was
performed using TMB liquid substrate system for membranes (Sigma).
2.6. Mass spectrometry (MS)
Inactivated culture supernatant obtained from the industrial process was
concentrated 20X by ultrafiltration (Vivaspin 500, 5 kDa, GE Healthcare) and
analyzed by SDS-PAGE and coomassie blue staining. The most defined and
intense bands were identified by peptide mass fingerprinting at Institut Pasteur
Montevideo (Uruguay) using a 4800 MALDI TOF/TOF Analyzer (Applied
Biosystems). Peptides from each sample were obtained by trypsin treatment
(Sequencing Grade, Promega) overnight at 37 °C. Peptide mass spectra were
acquired as previously described (Lima et al., 2011) and MS/MS collision induced
dissociation experiments of selected peptides were performed. Proteins were
identified by NCBInr database searching with peptide m/z values using MASCOT
search engine (Matrix Science) (Perkins et al., 1999) with the following searching
parameters: monoisotopic mass tolerance, 0.08 Da; fragment mass tolerance, 0.45
Da and one missing tryptic cleavage allowed. Significant scores (p < 0.05) were
used as criteria for positive protein identification.
3. Results
3.1. Mannheimia haemolytica laboratory scale fermentation
During M. haemolytica laboratory scale fermentation, parameters such as glucose
concentration, dissolved oxygen, optical density (OD600nm) and pH were
determined in samples taken every one hour of culture. This fermentation showed
a kinetic profile compatible with typical bacterial growth in a batch system
(Fig. 1B). Culture was harvested ten hours after fermentation start, at the beginning
of the stationary growth phase.
Supernatant samples of a M. haemolytica laboratory scale culture were analyzed in
order to evaluate the LKT accumulation in the supernatant. To identify LKT
specific anti-LKT antibodies were produced. In preliminary evaluation experi-
ments, we confirmed that these antibodies showed the expected reactivity against
native and recombinant LKT and a good specific antibody titer. By means of these
antibodies we identified LKT as a single defined band of approximately 110 kDa in
culture supernatant samples of M. haemolytica (Fig. 1A). In parallel, the presence
of LKT in this protein band was confirmed by MS analysis (MS/MS protein score
408, protein sequence coverage 36%).
The intensity of the specific LKT band detected by Western blot was determined
by molecular imaging software. This analysis showed that LKT expression
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correlates with growth kinetics, being associated with exponential growth phase of
M. haemolytica (Fig. 1B), as previously reported (Chang et al., 1987).
Therefore, the presence of LKT was verified in the culture supernatant of the M.
haemolytica production strain, during the exponential growth phase of the culture.
3.2. Proteomic characterization of M. haemolytica inactivated
culture supernatant
For proteomic analysis, industrial antigen was prepared according to vaccine
production protocol. Culture supernatant was obtained and concentrated by
ultrafiltration. After SDS-PAGE electrophoresis and coomassie blue staining,
selected bands were recovered for MS identification (Fig. 2A). This approach
allowed the statistically significant identification of 11 proteins of M. haemolytica
in the industrial antigen (Table 1). LKT was identified, in accordance with
previous results of laboratory scale fermentation, among other relevant proteins.
Some of these are outer membrane proteins (OMPs), which along with LKT are
critical to achieve a protective immunity to the pathogen (Lo et al., 1991; Singh
et al., 2011).
Subcellular in silico localization, predicted using free access PSORTb software
(available at http://psort.hgc.jp/), indicated that most of the identified proteins are
periplasmic (7/11), with others being extracellular (1/11) or located in the outer cell
membrane (2/11).
Although most proteins coincided with their theoretical MW (Table 1), LKT was
identified by MS in a higher than expected MW band (>230 kDa). This result was
confirmed by Western blot of inactivated supernatant using anti-LKT antibodies
[(Fig._1)TD$FIG]
Fig. 1. M. haemolytica culture growth and LKT secretion profile. A. Anti-LKT Western blot of M.
haemolytica culture supernatant samples from different fermentation time points. M: fermentation
media, T1–T10: samples from culture kinetics (1–10 h). MW: Molecular weight marker. B. M.
haemolytica culture growth curve and kinetics of Leukotoxin secretion. Optical density (OD) at 600 nm,
glucose concentration (mg/dL) and band intensity of LKT expressed in arbitrary units (AU) are plotted
versus culture growth time measured in hours.
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(Fig. 2B). This behavior of LKT in electrophoresis could be explained by cross-
linking caused by formaldehyde treatment leading to high molecular weight
structures.
Immune reactivity of a serum obtained from a M. haemolytica infected calf against
culture supernatant was addressed by Western blot. As shown in Fig. 2B several
bands of both inactivated and non inactivated culture supernatant were specifically
recognized by infected bovine serum and not by healthy bovine serum. Among
them, LKT was the more reactive band.
4. Discussion
This work provides an exhaustive molecular characterization of an inactivated
culture supernatant of M. haemolytica included in a line of polyvalent commercial
bovine vaccines (Neumosan, Virbac Uruguay). Since M. haemolytica is the main
etiological agent of BRD and is also responsible for a high proportion of the
[(Fig._2)TD$FIG]
Fig. 2. Identification of M. haemolytica culture supernatant proteins. A. M. haemolytica proteins of
inactivated culture supernatant (iCSN) resolved in SDS-PAGE and stained with coomassie blue. Bands
corresponding to the proteins analyzed by MS (MALDI TOF/TOF) are numbered and referred to on
Table 1. For complete image see Fig. S1 (Supplementary material). B. Analysis of culture supernatant
proteins by Western blot. Left: M. haemolytica inactivated (iCSN) and non inactivated culture
supernatant (CSN) proteins probed with anti-rLKT rabbit serum. Middle: Reactivity of bovine M.
haemolytica infected serum against M. haemolytica iCSN and CSN. Right: Reactivity of bovine healthy
serum against M. haemolytica iCSN and CSN. MW: Molecular weight marker.
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Table 1. Proteins identified in culture supernatant of M. haemolytica.
Gel reference
(Fig. 2A)
Protein Gene symbol MS/MS
scores*
ID (Uniprot) M.W. Subcellular
Location
Additional Information
1 Leukotoxin A lktA 121 I1W261 102.1
kDa
Extracellular Involved in pathogenesis and calcium ion binding (Vougidou et al.,
2013).
2 Serotype-specific antigen 1 ssa1 235 P31631 103.6
kDa
Outer Mem-
brane
Associated to serotype change in the bovine upper respiratory tract
after stress. May have protective vaccine potential (Lo et al., 1991;
Ayalew et al., 2011).
3 Formate C-acetyltransferase pflD 88 E2PBB6 86.7
kDa
Cytoplasmic Piruvate metabolism, acetiltransferase activity (Lawrence et al.,
2010).
4 2‘ 3'-cyclic-phosphodiesterase/
3'-nucleotidase
cpdB 167 M9X363 72.8
kDa
Periplasmic Nucleotide metabolism (Eidam et al., 2013).
5 Oligopeptide ABC superfami-
ly transporter, binding protein
oppA 133 M9X4S4 61.0
kDa
Periplasmic ABC transporter system component involved in molecule export
through bacterial membrane (Eidam et al., 2013).
6 Extracellular solute-binding
protein family 5
MHH_RS20960 211 A0A0B5BMJ5 57.9
kDa
Periplasmic ABC transporter system component involved in peptide transmem-
brane transport (Harhay et al., 2013).
7 Heme-binding protein A MHH_RS16715 168 A0A0B5BSE3 59.6
kDa
Periplasmic Similar to antimicrobial peptide ABC transporter periplasmic
binding protein SapA (Harhay et al., 2013).
8 Iron (Fe3+) binding protein yfeA 212 S9Y6G0 33.0
kDa
Periplasmic Cellular adhesion and iron transport (Hauglund et al., 2015).
9 TRAP transporter solute re-
ceptor TAXI family-periplas-
mic binding protein
MHH_RS16825 130 M9X2M0 34.5
kDa
Periplasmic Extracytoplasmic solute-receptor-dependent secondary active trans-
porter (Rabus et al., 1999; Eidam et al., 2013).
10 HisJ-like histidine ABC trans-
port system-periplasmic bind-
ing protein
MHH_RS14805 328 M9WWE6 28.0
kDa
Periplasmic ABC transporter system component involved in molecule export
through bacterial membrane (Eidam et al., 2013).
11 Outer membrane protein P6 pal 121 M9X7K9 16.8
kDa
Outer Mem-
brane
Belongs to ompA family (Eidam et al., 2013). Ortholog Omp P6
reported as immunogen in other species (Roier et al., 2013; Alvarez
et al., 2015).
* For this search protein scores greater than 87 are significant (p < 0.05).
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disease associated morbid-mortality (Potter, 2015), this kind of information is of
utmost importance.
Available data demonstrate that the protective immunity against M. haemolytica
can be acquired by neutralizing antibodies against Leukotoxin A (Mosier et al.,
1989), as well as antibodies against bacterial cell surface antigens (Shewen and
Wilkie, 1988; Confer et al., 1995; Confer et al., 2009). In order to promote an
effective immune response, the presence of these pivotal elements in a BRD
vaccine formulation is crucial.
Based on previous reports that detected Leukotoxin A activity in bacterium-free
culture supernatant from logarithmic-phase cultures (Chang et al., 1987),
Neumosan line of vaccines includes inactivated culture supernatants of an
industrial optimized M. haemolytica culture. In this work we confirmed that
LKT secretion is linked to the exponential growth phase during the antigen
production culture, representing one of the primary secreted components. In
culture supernatant, LKT was detected as a single band with the expected MW
(approx. 110 kDa) (Lo et al., 1985; Chang et al., 1987). Interestingly, after
formaldehyde treatment, LKT was detected as a higher MW band (>230 kDa),
suggesting that the toxin could be arranged as a high order structure, which
could be fixed by this cross-linking agent (Klockenbusch and Kast, 2010). This
finding is in agreement with previous reports that showed that the molecular
weight of native LKT in culture supernatant was higher than 400 kDa (Chang
et al., 1987).
Besides LKT identification, we delved further into the characterization of the
culture supernatant protein profile. By MS we identified other 10 proteins of M.
haemolytica. Most of them are periplasmic and outer membrane proteins, which
due to their extracellular location and exposure to the host immune system could
represent interesting candidates to play a key role in the protection against this
pathogen. It is worth mentioning that we also identified a cytoplasmic protein
involved in carbohydrate metabolism (Formate C-acetyltransferase). This finding
could be explained by some cellular lysis that could occur during bacterial growth
and inactivation (Derzelle et al., 2005), hence we cannot rule out that the culture
supernatant may contain some cytoplasmic proteins.
Some of the outer membrane proteins identified in this work have been reported as
important immunogens and have been evaluated as recombinant subunit antigens
due to their protective vaccine potential (Ayalew et al., 2011; Guzman-Brambila
et al., 2012). In particular, vaccination of mice and cattle with recombinant
serotype specific antigen 1 (rSsa1) stimulated high antibody responses (Ayalew
et al., 2011). Besides, a “Best-Reciprocal-Blast-Hit” approach was performed in
order to determine that M. haemolytica outer membrane protein P6 identified in
this work, is ortholog to Omp P6 of H. somni and P. multocida, both reported as
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immunogenic in recent reports (Roier et al., 2013; Alvarez et al., 2015). In that
sense, the natural occurrence of these proteins in the inactivated vaccine antigen
indicates that the vaccine contains the main components required for protection
against M. haemolytica.
Different proteins belonging to the ATP-binding cassette (ABC) transporter
superfamily were identified in the commercial antigen. ABC transport systems are
essential for many processes of the cell, such as uptake of amino acids, peptides,
carbohydrates and metal ions in an ATP coupled process. There is increasing
evidence that these transport systems play either direct or indirect roles in the
virulence and pathogenicity of bacteria (Garmory and Titball, 2004). In a recent
work, other ABC transporters were identified as immunodominant proteins from
M. haemolytica and H. somni in cattle immunized with a commercial cellular
vaccine, confirming that the surface exposed transporters of these species are
immunogenic (Alvarez et al., 2015). Interestingly, our results evidence that ABC
transporters are relevant components in the vaccine antigen, and therefore could be
potential targets for the development of antibacterial subunit vaccines (Garmory
and Titball, 2004).
Finally, we also identified an iron-regulated periplasmic protein YfeA, previously
described as immunodominant in animals immunized with a cellular
M. haemolytica vaccine (Alvarez et al., 2015), as well as with an OMP-enriched
fraction of M. haemolytica (Ayalew et al., 2010).
Taken together, these observations support the protective potential of several of the
proteins indentified in the M. haemolytica antigen. As an additional outcome anti-
LKT antibodies developed for LKT identification can be used in routine
quantitative assays in order to establish acceptance criteria of antigen commercial
batches.
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